Q-omics provides the consensus-scored C11orf45 profile across patient tissues and cancer cell-line models. C11orf45 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C11orf45 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, C11orf45 RNA expression shows 17,511 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where C11orf45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf45 survival associations across molecular data types. C11orf45 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf45 RNA expression–survival associations across cancer types. High C11orf45 expression shows unfavorable associations in UVM, KIRC, UCEC, LGG and CESC, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for C11orf45 RNA expression.
This table summarizes C11orf45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C11orf45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf45 shows lower tumor expression in LUAD, KICH and KIRC and higher tumor expression in HNSC, BLCA and LIHC. The HNSC box plot shows higher C11orf45 RNA expression in tumor versus normal tissue (log2 FC = +0.972, t-test p < 0.001).
This table shows molecular features associated with C11orf45 in patient tissues and cancer cell lines. In patient samples, C11orf45 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
